Inflammation of the Nasal Mucosa is Associated with Susceptibility to Experimental Pneumococcal Challenge in Older Adults.

Streptococcus pneumoniae colonization mucosal immune responses older adults

Journal

Mucosal immunology
ISSN: 1935-3456
Titre abrégé: Mucosal Immunol
Pays: United States
ID NLM: 101299742

Informations de publication

Date de publication:
29 Jun 2024
Historique:
received: 01 03 2024
revised: 25 06 2024
accepted: 26 06 2024
medline: 2 7 2024
pubmed: 2 7 2024
entrez: 1 7 2024
Statut: aheadofprint

Résumé

Streptococcus pneumoniae colonization in the upper respiratory tract is linked to pneumococcal disease development, predominantly affecting young children and older adults. As the global population ages and comorbidities increase, there is a heightened concern about this infection. We investigated the immunological responses of older adults to pneumococcal controlled human infection by analysing the cellular composition and gene expression in the nasal mucosa. Our comparative analysis with data from a concurrent study in younger adults revealed distinct gene expression patterns in older individuals susceptible to colonization, highlighted by neutrophil activation and elevated levels of CXCL9 and CXCL10. Unlike younger adults challenged with pneumococcus, older adults did not show recruitment of monocytes into the nasal mucosa following nasal colonization. However, older adults who were protected from colonization showed increased degranulation of CD8+ T cells, both before and after pneumococcal challenge. These findings suggest age-associated cellular changes, in particular enhanced mucosal inflammation, that may predispose older adults to pneumococcal colonization.

Identifiants

pubmed: 38950826
pii: S1933-0219(24)00064-3
doi: 10.1016/j.mucimm.2024.06.010
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Britta C Urban (BC)

Oxford Vaccine Group, University of Oxford, Oxford, United Kingdom; Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom; NIHR Oxford Biomedical Research Centre, Oxford, UK. Electronic address: Britta.urban@paediatrics.ox.ac.uk.

André N A Gonçalves (ANA)

Oxford Vaccine Group, University of Oxford, Oxford, United Kingdom; Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom; NIHR Oxford Biomedical Research Centre, Oxford, UK.

Dessi Loukov (D)

Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

Fernando M Passos (FM)

Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

Jesús Reiné (J)

Oxford Vaccine Group, University of Oxford, Oxford, United Kingdom; Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom; NIHR Oxford Biomedical Research Centre, Oxford, UK.

Patrícia Gonzalez-Dias (P)

Oxford Vaccine Group, University of Oxford, Oxford, United Kingdom; Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom; NIHR Oxford Biomedical Research Centre, Oxford, UK.

Carla Solórzano (C)

Oxford Vaccine Group, University of Oxford, Oxford, United Kingdom; Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom; NIHR Oxford Biomedical Research Centre, Oxford, UK.

Elena Mitsi (E)

Oxford Vaccine Group, University of Oxford, Oxford, United Kingdom; Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom; NIHR Oxford Biomedical Research Centre, Oxford, UK.

Elissavet Nikolaou (E)

Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom; Infection, Immunity and Global Health, Murdoch Children's Research Institute, Parkville, Victoria, Australia; Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, Victoria, Australia.

Daniel O'Connor (D)

Oxford Vaccine Group, University of Oxford, Oxford, United Kingdom; NIHR Oxford Biomedical Research Centre, Oxford, UK.

Andrea M Collins (AM)

Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom; University Hospital Aintree, Liverpool University Hospitals Trust, Liverpool, UK.

Hugh Adler (H)

Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

Andrew Pollard (A)

Oxford Vaccine Group, University of Oxford, Oxford, United Kingdom.

Jamie Rylance (J)

Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

Stephen B Gordon (SB)

Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom; Malawi-Liverpool-Wellcome Clinical Research Programme, Blantyre, Malawi.

Simon P Jochems (SP)

Leiden University Centre for Infectious Diseases, Leiden University Medical Centre, Leiden, the Netherlands.

Helder I Nakaya (HI)

Hospital Israelita Albert Einstein, São Paulo, Brazil; Department of Clinicsupal and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.

Daniela M Ferreira (DM)

Oxford Vaccine Group, University of Oxford, Oxford, United Kingdom; Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom; NIHR Oxford Biomedical Research Centre, Oxford, UK. Electronic address: Daniela.ferreira@paediatrics.ox.ac.uk.

Classifications MeSH